Aminoglycosides Market: By Drug Type (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Other Aminoglycosides), By Mode of Administration (Feed, Injectables, Intra-mammary, Topical, Oral), By Applications (Veterinary, Skin, Respiratory, UTI & Pelvic Disease, Neonatal Sepsis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and others, and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Aminoglycosides Market size is valued at USD 1.68 billion in 2022 and is expected to reach USD 2.09 billion by 2028, at a significant CAGR of 3.6% from 2023-2029. Aminoglycosides are administered in a variety of ways, depending on the type and location of infection, as well as whether the medicine is for a human or non-human patient. These can be given as a feed, an injection (parenteral), an intra-mammary, an oral, or a topical treatment. Injectable administration accounted for the majority of the market, as this method is chosen for human medical use since it gives the best form of drug action mechanism via intravenous or intramuscular treatment. The oral administration of an aminoglycoside antibiotic is typically used to prevent infection during intestinal surgery. However, the low absorption rate of these antibiotics is one of the reasons behind the route's lower revenue share. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Aminoglycosides Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Aminoglycosides Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Global Aminoglycosides Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.6%

Largest Market

North-America

Fastest Growing Market

North America
Aminoglycosides Market Dynamics

This class of antibiotics has been discovered to be effective even in the presence of a substantial bacterial inoculum, and it is routinely employed as a second line of defence against infections that are resistant to basic antibacterials. This treatment-related application of medications in this class is projected to be a key driver of growth.

Key Features of the Reports

  • The aminoglycosides market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startups details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market

 

 

Global Aminoglycosides Market Segmentation

By Drug Type
  • Neomycin
  • Tobramycin
  • Gentamicin
  • Amikacin
  • Paromomycin
  • Streptomycin
  • Kanamycin
By Mode of Administration
  • Feed
  • Injectables
  • Intra-mammary
  • Topical
  • Oral
By Application
  • Veterinary
  • Skin
  • Respiratory
  • UTI & Pelvic Disease
  • Neonatal Sepsis
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
By Geography
  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The Aminoglycosides market size was valued at USD 1.68 billion in 2022.

The key segments covered in the restless leg’s syndrome market are technology, components, application, and end-users.

The Aminoglycosides market key player is Cipla Limited, Pfizer Inc, AbbVie Inc. (Allergan PLC), Novartis AG, Johnson & Johnson, Bristol Myers Squibb Company, Vega Pharma Ltd, Xian Wison Biological Technology Co. Ltd, Yi Chang Veterinary Medicine Factory, Insmed Incorporated, Teva Pharmaceutical Industries Ltd, Achaogen Inc, Sun Pharmaceutical Industries Limited, Chiesi Farmaceutici, Zoetis Inc.

 
  • Cipla Limited
  • Pfizer Inc
  • AbbVie Inc. (Allergan PLC)
  • Novartis AG
  • Johnson & Johnson
  • Bristol Myers Squibb Company
  • Vega Pharma Ltd
  • Xian Wison Biological Technology Co. Ltd
  • Yi Chang Veterinary Medicine Factory
  • Insmed Incorporated
  • Teva Pharmaceutical Industries Ltd
  • Achaogen Inc
  • Sun Pharmaceutical Industries Limited
  • Chiesi Farmaceutici
  • Zoetis Inc.

Adjacent Markets